Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48 | $45 | $46 | $46 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Cost of Goods Sold | $21 | $20 | $20 | $20 |
| Gross Profit | $27 | $25 | $26 | $27 |
| % Margin | 56.8% | 56.3% | 57.4% | 57.7% |
| R&D Expenses | $10 | $9 | $9 | $10 |
| G&A Expenses | $6 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $8 | $8 | $8 |
| Sales & Mktg Exp. | $2 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18 | $17 | $17 | $17 |
| Operating Income | $10 | $8 | $9 | $10 |
| % Margin | 20% | 18.8% | 20.1% | 20.6% |
| Other Income/Exp. Net | -$18 | -$0 | -$2 | -$1 |
| Pre-Tax Income | -$8 | $8 | $8 | $8 |
| Tax Expense | $1 | $0 | $1 | $1 |
| Net Income | -$9 | $8 | $6 | $7 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | -4.41 | 3.88 | 2.97 | 3.15 |
| % Growth | -213.7% | 30.6% | -5.7% | – |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $1 |
| Depreciation & Amortization | $10 | $10 | $10 | $11 |
| EBITDA | $3 | $19 | $19 | $20 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |